



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Analyst briefing on Chi-Med’s pharmaceutical R&D business on 9 October 2013**

**London: Thursday, 3 October 2013:** Chi-Med today announces that it will host a briefing to update investors and analysts on Hutchison MediPharma (“HMP”), its majority owned pharmaceutical R&D division, in London on 9 October 2013.

Over the past several years, HMP has built an impressive pipeline of oral, small molecule cancer drugs and proprietary botanical drugs for inflammatory diseases. The briefing will focus on this pipeline.

HMP’s current clinical pipeline includes: Fruquintinib, Sulfatinib, Epiteinib, Theliatinib and Volitinib, each of which has the potential to treat a number of cancers, and HMPL-004, its lead candidate for ulcerative colitis and Crohn’s disease.

In addition, HMP has formed key partnerships with major global pharmaceutical companies, including AstraZeneca and Nestlé Health Science.

The briefing will also cover HMP’s pre-clinical research and the ongoing Phase III clinical development of HMPL-004, which is being undertaken by Nutrition Science Partners, a 50:50 joint venture between Chi-Med and Nestlé Health Science.

During the briefing, Dr Andrew Mortlock, Vice President of Cancer Research and Development Projects of AstraZeneca will give a presentation entitled, “Oncology in China”.

Other key presenters at the briefing will be:

- Dr Weiguo Su, Ph.D. Chief Scientific Officer of HMP. Prior to joining HMP, Dr Su spent fifteen years with Pfizer’s US R&D organisation where he was responsible for the delivery of several high quality new drug candidates into the clinic.
- Dr Hua Mu, Chief Medical Officer of HMP. Prior to joining HMP, Dr Mu worked at Roche, Biogen Idec, Abraxis and most recently, Genentech. During his career, he has been involved in the development of a number of successful oncology drugs including Xeloda<sup>®</sup>, Abraxane<sup>®</sup> and Avastin<sup>®</sup>.

Mr Christian Hogg, Chief Executive Officer of Chi-Med, and Mr Johnny Cheng, Chief Financial Officer of Chi-Med, will also give presentations covering HMP’s overall R&D strategy and its funding.

The briefing will take place at The Brewery (The James Watt room), 52 Chiswell Street, London, EC1Y 4SD on 9 October 2013 at 9:30 am, with registration starting from 9:15 am. Please contact Ms Janine Hagan by email at [janine.hagan@citigatedr.co.uk](mailto:janine.hagan@citigatedr.co.uk) for registration.

## Ends

### Enquiries

#### **Chi-Med**

Christian Hogg, CEO

Telephone: +852 2121 8200

#### **Panmure Gordon (UK) Limited**

Richard Gray  
Andrew Potts  
Grishma Patel

Telephone: +44 20 7886 2500

#### **Citigate Dewe Rogerson**

Anthony Carlisle  
David Dible

Telephone: +44 20 7638 9571  
Mobile: +44 7973 611 888  
Mobile: +44 7967 566 919

### Notes to Editors

#### **About HMP**

HMP is a novel drug R&D division focusing on discovering, developing and commercialising innovative therapeutics in oncology and autoimmune diseases. With a team of around 200 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.

HMP is majority owned by Chi-Med. For more information, please visit: [www.hmpglobal.com](http://www.hmpglobal.com).

#### **About Chi-Med**

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited. For more information, please visit: [www.chi-med.com](http://www.chi-med.com).